Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

657895.pdf (411.63 KB)

Document type

Article

Version

Published version

Publication date

2015-08

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/110383

Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1136/annrheumdis-2015-207530

Abstract

We read with great interest the paper by Chen et al1 analysing the relationship between therapeutic response to adalimumab and etanercept and serum drug trough levels in 70 patients with rheumatoid arthritis (RA). ...

Description

Article en format correspondència

Subject

Artritis reumatoide, Medicaments, Administració de medicaments, Sistema immunològic, Anticossos monoclonals

Subject (English)

Rheumatoid arthritis, Drugs, Administration of drugs, Immune system, Monoclonal antibodies

Citation

Collections

Articles publicats en revistes (Ciències Clíniques)

Citation

SANMARTÍ SALA, Raimon, et al. Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. Annals of the Rheumatic Diseases. 2015. Vol. 74, num. 8, pags. e42. ISSN 0003-4967. [consulted: 8 of August of 2026]. Available at: https://hdl.handle.net/2445/110383

Export metadata

JSON - METS

Share record